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1078-l 78 Application of Synthetic CDK lnhibitlon (Flavopiridol) as 
a Novel Therapeutic Strategy to Effectively Limit 
Common Pathways of In-Stent Restenosis: 
Characterization of Molecular Effects and Applicability 
on Drug Coated Stents 
Birgit Jaschke, Franziska Wegener, Sr., Rainer Wessely, Deutsches Herzzentrum. 
Muenchen. Germany 
The cellular component of in-stem restenotic lesions is mainly comprised of proliferated 
and migrated coronary artery smooth muscle cells (CASMC). Early ceil cycle inhibition 
represents an attractive therapeutic strategy. Cyclin-dependent kinases (CDK) trigger 
and coordinate transitions between different phases of the cell cycle. Flavopiridol (FLA) 
is a highly effective synthetic CDK inhibitor. The main purpose of the study was to deter- 
mine the efficacy and molecular effects of FLA in limiting mitogen induced CASMC prolif- 
eration and migration as well as to examine the effects of FLA coated stems on the 
prevention of in-stem restenosis. Results: FLA displayed potent anti-proliferative effects 
in CASMC, the IC50 was determined at 75 nM (BrdU ELISA. cell counting). Accordingly, 
CASMC CDW, 4 and PCNA protein levels were dose dependently downregulated. Cell 
cycle analysis by propidium iodine flow cytometry revealed a Gt arrest in Flavopirldol 
treated CASMC. Given the potent anti-restenotic effects of Sirolimus coated stems, 
upregulated levels of endogenous CDK inhibitors such as p21 and particularly p27 may 
be critical for effective anti-restenotic therapy. FLA lead to a dose dependent increase of 
p21 and p27 protein levels in CASMC. FLA prevented p27 degradation. At concentra- 
tions of lOOnM, there was neither evidence of FLA induced cytotoxicity (LDH release 
ELISA) nor apoptosis (ssDNA ELISA). A Boyden chamber assay revealed significant 
reduction of CASMC migration towards a fibronectin gradient by more than 50% at 100 
nM. FLA coated stents lead to significant inhibition of CASMC proliferation in an in vitro 
model (FLA 137+/-12 cells, control 454~1-46, p<O.Ol). Initial results in an ongoing study 
using a rat carotid stenting model indicate reduced neointima formation in animals 
treated with FLA coated stents. Conclusions: Flavopiridol displays potent anti-restsnotic 
effects. CDK inhibition by novel synthetic compounds such as Flavopiridol via drug 
coated stems may be an effective approach to limit neointima formation following stem 
placement and highlights the importance of early cell cycle inhibition as an effective tool 
to limit restenotic processes. 
1078-l 79 Interferon Gamma Receptor 1 88 G/A Polymorphism 
and Restenosie Following Coronary Artery Stenting 
Klaus A. Tiroch, Olga Gorchakova, Werner Koch, Petra Hoppmann. Angela Ehrenhaft, 
Wolfoano L&z. Nicolas van Beckerath. Albert Schomia. Adnan Kastrati. Deutsches 
He&en&urn MOnchen, Munich, Germany, 1. Medizinische Klinik der Technischen 
Universitat Munchen. Munich, Germany 
Background: Recently, upregulation of interferon gamma related genes has been found 
in human neointima of restenotic lesions following coronary artery stenting. The func- 
tional single nucleotide polymorphism 66GlA is located inside the signal peptide of the 
interferon gamma receptor 1 and results in an amino acid substitution (ValldMet). The 
objective of this study was to assess the influence of this polymorphism on restenosis. 
Methods: This is a case control study. Subjects of both groups were nondiabetics with 
stenting in 2 or more vessels and follow-up angiography at 6 months. Cases were 
selected to have restenosis in at least 2 stented lesions and controls no restenosis at all. 
Each group consisted of 41 consecutive patients fulfilling these criteria. Genotyping was 
performed with nested PCR and restriction enzyme analysis. 
Results: Cases were 67.6+12.9 years old, controls 67.5+12.0 years. None of the cases 
or controls were homozygous for the rarer A allele. An excess of A allele carriers was 
observed among cases with restenosis as compared to controls (Figure). 
Conclusions: Interferon gamma receptor 1 66GlA polymorphism may have an influence 
on the development of restenosis following coronary artery stenting. This may be related 
to a shift of ThlKhP balance described for A allele carriage. 
1078-l 80 Circulatory Endothelial Precursor Cells and Neural- 
Crest Derived Cells in Human In-Stent Restenosis 
Dirk Skowasch. Kristina Yeahiazawan Sabine Dinkelbach, Alexander Jabs, Bemdt 
LOderitz, Gerhard Bauriedel, University of Bonn, Bonn, Germany 
Background: In-stem restenosis (ISR) is a major limitation of interventional cardiology. 
Circulatory endothelial precursor cells and neural crest derived cells might contribute to 
neointimal formation as reparation cells. Therefore, the objective of the present study 
was to evaluate CD34 and CD133 as markers of bone-marrow derived cells, and cal- 
cium-binding protein SIOO, glial fibrillary acidic protein (GFAP), neuron-specific enolase 
(NSE) and nerve growth factor receptor (NGFR) as markers for neural crest derived cells 
in ISR Methods: Atherectomy specimens from 10 patients with coronary (post-stem 
implantation 6$3) months), 7 patients with peripheral ISR (723) and 10 with primary 
lesions were studied by immunohistochemistry for the presence of each determinant. 
Results: Samples from ISR consrstently demonstrated a homogeneous hypercellularity 
(12122546 celUmm2 III coronary, 10612257 in peripheral ISR, 665+96 in primary 
lesions). As a key finding, expression of each marker was significantly increased in ISR 
compared to primary lesions (each P.zO.05; Table). In addition, we found positive correla- 
tions for cells of bone-marrow and neural-crest origin. Conclusion: The present study 
demonstrates the presence of intimal cells of bone marrow and neural crest origin in dif- 
ferent types of coronary and peripheral atherosclerosis. Their significant expression in 
human ISR suggests an important role of these cells in this form of accelerated athero- 
sclerosis. 
Coronary ISR Peripheral ISR Pnmary lesion 
CD34 5.722.5 
CD133 7.2i4.l 
SfOO 10.Q6.7 
GFAP 8.2i3.9 
NSE 4.122.9 
NGFR 4.5i2.3 
9.ls.6 0.6+_0.7 
6.79.0 I.&O.7 
6.7+4.1 l&l.1 
7.5i1.9 3.1+1 .o 
4.69.1 l&l .6 
3.7i2.7 1.1+0.7 
1078-181 The Effect of Carvedilol-Loaded SiodyvYsio Stent on 
Neointimal Hyperplasia in a Porcine Coronary Stent 
Restenosis Model 
Weon Kim,Mvuna Ho Jeonq Gwang Soo Cha. Young Joon Hong, Jeong Gwan Cho. 
Jong Chun Park, Jung Chaee Kang, Chonnam National University Hospital, Gwang Ju, 
South Korea, Dong A University Hospital, Busan, South Korea 
Background and Purpose: Catvedilol is a direct inhibitor of myofibroblast migration in 
the vascular media and adventitia and exhibits antioxidant properties. We assessed the 
efficacy of high concentration of carvedilol, loaded with BicdivYsioTM DD stent and deliv- 
ered directly into the vessel wall on the inhibition of neointimal proliferation after stenting 
in porcine coronary arteries. Methods: Total loading amount of carvedilol was deter- 
mined using 11 mm BiafivYsioTM Matrix LO stents in different concentration (5mglmL. 
25mg/mL, and 40mglmL) of carvedilol solution. Twenty-two BiodivYsi@ DD stems were 
implanted at 12 pigs, immediately after being immersed and dried in the different 
carvedilol or control solution. Quantitative angiographic analysis and histopathologic 
analysis was done 4 weeks later. Results: Total loading amounts of carvedilol on the 
BicdivYsioTM Matrix LO stents were 7il pg, 96t18 pg. and 217+34 pg from 5 mgiml, 25 
mglml, and 50 mglml carvedilol solution, respectively. Twenty-two stems were implanted 
and overexpanded successfully. No pig was dead during the 4-week observation. On 
quantitative coronary angiogram, the coronary artery diameters were not significantly dif- 
ferent between two groups before stenting or at 4 weeks after stenting. 
Table. Histopathologic analysis 
Control 5mglmL 25mgimL 4OmglmL P value 
Injury score 1.60*0.63 1.92*0.64 1.92iO.64 1.76~0.59 0.69 
EIL area (mm*) 7.17+0.97 7.15t0.60 6.36iO.43 6.76tl.16 0.067 
IIL area (mm? 5.35*0.75 6.06*0.56 5.23*0.61 5.57*1.12 0.084 
Lumen area (mms) 3.7220.78 5.16*0.66 3.92iO.66 4.44tl.40 0.004’ 
Neointima (mm? 1.63i0.56 0.8&0.30 1.3liO.73 1.13+0.57 0.022’ 
Diameter stenosis (%) 30.5*10.5 14.625.2 25.2~13.4 21.7kl4.5 0.016’ 
’ P.zO.05 between 5 mg/ml and control solution. 
Conclusions: Low dose carvedilol-loaded BiodivYsidM Matrix LO stems inhibit stem 
restenosis in porcine coronary stem restenosis model. 
1078-l 82 Innate lmmunomodulation via Transient Depletion of 
Monocytes by Liposomal-Alendronate Suppresses 
Neointimal Formation Following Balloon and Stent 
Injury in Rabbits 
Haim D. Danenberq Gershon Golomb, Adam R. Groothuis, Philip Seifert. Elazer R. 
Edelman, Massachusetts Institute of Technology, Cambridge, MA, Hebrew University of 
Jerusalem, Jerusalem, Israel 
Background: Inflammation is a major trigger for the reparative events that follow vascular 
injury. Excessive innate immune response correlates with neointimal hyperplasia and 
restenosis. We studied the impact of transient systemic inactivation of monocytes and 
macrophages on intimal hyperplasia following balloon injury and stem deployment. 
Methods and Results: Bisphosphonates encapsulated in liposomes are phagocytosed by 
and specifically inactivate macrophages. Endothelial or smooth muscle cells that do not 
imbibe these formulations are left intact. Rabbits fed a hypercholesterolemic diet under- 
went bilateral iliac balloon denudation and stent deployment. Suppression of blood 
monocytes from 94tlt3 to l&15 I ml (p<O.Ol) was observed 46 hours after injury and 
intraarterial inJection of liposomal alendronate (3 mg/kg). Suppression was transient with 
return to normal levels a week after iniuw (flow cvtometrv for CDl4+ cells). The reduction 
in blood monocytes was associated with reduced infiltration by tissue macrophages (at 6 
davs. RAM-1 1 rmmunostainino). suooressed arterial cellular oroliferation (KI-67 immun- 
ostarning) and neointimal formation at 28 days. lntimal area was reduced by 47% 
(3.68*0.93 to 2.08t0.56 mm2), lumen area was increased by 24% (2.87eO.44 to 
3.57*0.65 mm2) and stenosis (%) was reduced by 25% (342 4 to 25* 4%) (mean&D, 
n=l6, peO.01 for all 3 parameters). 
Conclusions: Innate immunity triggers vascular repair; and when extreme, as in stented 
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vessels, can lead to excessive proliferation. Transient systemic inactivation of monocytes 
and macrophages by liposomal alendronate reduced neointrmal formation and restenosis 
in the stented hypercholesterolemrc rabbit model in a manner that can be used indepen- 
dent of Stent number, positron, or overlap and with possible multiple dosing. 
1078-183 The Endothelial Nitric Oxide Synthase (Glu298Asp and - 
788T>C) Gene Polymorphisms Are Associated With 
Coronary In-Stent Restenosis 
Abuzeid Gamma. Mohamed Elrayess, Charles Knight, Emma Hawe, Kim Fox, Steve 
Humphries, National Heart and Lung Institute and Royal Brompton Hospital, London, 
United Kingdom, British Head Foundation Laboratories for Cardiovascular Genetic 
Studies, UCL Medical School, London, United Kingdom 
Background Coronary stent deployment is a major advance in percutaneous treatment 
of ischaemic heart disease, but 1 O-40% of patients strll develop angiographic restenosis 
by 6 months due to neointimal hyperplasia. Patient-specific factors, includmg genetic fac- 
tors, can contribute to this process. We have conducted a prospective study to examme 
the involvement of genetic risk factors (eNOS, ACE, MMP-3, IL-6, and PECAM-1) in res- 
tenosis followmg coronary stent deployment. 
Methods 226 patients who underwent elective coronary artery stenting to de nova 
lesions in native coronary arteries were studied. 205 (90.7%) patients were restudied by 
coronary angiogram at 6 months and the stented lesions were assessed with automated 
quantitative angiography system. Genotype was determined by PCR and restriction 
enzyme digestion. Results Restenosis rate, defined as 250% diameter stenosis, was 
29.3%. The overall genotype frequency distributions were in Hardy-Weinberg equilibrium 
for all variants. Carriers of the 298Asp allele of the eNOS Glu298Asp polymorphism 
showed a higher frequency of restenosis with an odds ratio of 1.88 (95%CI:1.01-3.51, 
p=O.O43) compared to 298Glu homozygotes. Carriers of the -766C allele of the eNOS - 
786Tz.C polymorphism also showed a higher frequency of restenosis with odds ratio of 
2.06 (95%Cl:l.O8-3.94, p=O.O28). Other studied genes did not show significant associa- 
tion with coronary in-stent restenosrs. 
Conclusions In patients with coronary artery disease, the possession of the 296Asp and 
-7866 variants of the eNOS gene is a risk factor for coronary in-stent restenosis, dsmon- 
strating the importance of the nitric oxide system in restenosis. 
ORAL CONTRIBUTIONS 
805 Drug-Eluting Stents 
Monday, March 31, 2003, 9:15 a.m.-lo:30 a.m. 
McCormick Place, Room 5401 
9:15 a.m. 
805-1 Two-Year Follow-Up of the RAVEL Study: A 
Randomized Study With the Sirolimus-Eluting Bx 
VELOCITY Stent in the Treatment of Patients With De- 
Novo Native Coronary Artery Lesions 
Marie-Claude Morice, Patrick Serruys. Costantino Costantini, Egon Wuelfert, William 
Wiins. Jean Faiadet. Antonio Columbo. Giulio Guaoliumi. Ferenc Molnar. Ernest0 Ban , 
Hayashi. Jose Eduardo M. Sousa, Marco Perin, on behalf of the RAVEL Trial 
Investigators, lnstitut Cardiovasculaire Paris Sud. Massy, France 
Background: Sirolimus, a macrocyclic antibiotic and immunosuppressant, causes late 
Gl cell cycle arrest. A pilot study using Sirolimus-eluting stents (SES) to treat coronary 
arten, lesions demonstrated almost no neointimal hvoerolasia at 12 months. Results from 
this study were used to design RAVEL, a multicenter. double blind, two-arm, randomized 
studv assessino safetv and effectiveness of the Sirolimus-elutino Bx VELOCINTU stem 
1  .  
versus the uncoated Bx VELOCITYTM stent (16 mm). Methods: The primary endpoint 
was angiographic late loss at 6 months. The secondary endpoints were major adverse 
cardiac events, target vessel revascularization (n/R), target lesion revascularization 
(TLR) and restenosis rate. Inclusion criteria: stable or unstable angina, single trsatment- 
de nova lesions < 16mm long, 2.5-3.5 mm diameter. Clopidogrel or Ticlodipine was con- 
tinued for up to 8 weeks following a loading dose. Results: From August 2000Decem 
ber 2000. 236 patients were enrolled at 19 sites in Europe and South America. Baseline 
demographics and lesion characteristics were evenly distributed. No acute, subacute or 
late thrombosis occurred. One year results. 
Sirolimus Control P-value 
Reference diameter (mm) 2.60 
MLD Post-procedure (mm) 2.43 
MLD Follow-up (mm) - 6 month 2.42 
Late loss (mm) 0.01 
Restenosis rate (%) 0.0 
TLR-free - 1 year 99.2 
TV&free - 1 year 96.3 
TVF-free - 1 year 95.6 
MACE-free - 1 year 94.1 
2.64 NS 
2.41 NS 
1.64 .OOOl 
0.60 .OOOl 
26.1 .OOOl 
66.0 .OOOl 
64.3 .OOOl 
80.3 .OOOl 
81.2 .OOOl 
Conclusion: The QCA data demonstrate virtually no neointimal in-stent proliferation with 
event-free survival of 94% at one year in the SES treatment group. Two-year clinical fol- 
low-up data will be presented. 
9:30 a.m. 
805-2 Cost-Effectiveness of Sirolimus Drug-Eluting Stents for 
the Treatment of Complex Coronary Stenoses: Results 
From the Randomized SIRIUS Trial 
David J. Cohen, Ameet Bakhai, Chunrue Shi, Lourse Githiora, Ronna H. Berezin, Ronald 
P. Caputo, Charles O’Shaugnessy, Martin B. Leon, Jeff Moses, &chard E. Kuntz, on 
behalf of the SIRIUS Investigators, Beth Israel Deaconess Medical Center, Boston, MA, 
Harvard Clinical Research Center, Boston, MA 
Background: Previous studies have demonstrated that sirolimus drug-eluting stants 
(DES) dramatically reduce angiographic and clinical restenosis compared with conven- 
tional stenting. However, the cost-effectiveness (C/E) of DES in routine clinical practice is 
unknown. Methods: We prospectively measured medical resource utilization and cost 
for 1100 PCI patients randomized to either sirolimus DES or bare stems (BS) as part of 
the SIRIUS trial. Costs were assessed from the U.S. societal perspective, and each DES 
was assumed to cost 53000/stent. Results: Resource utilization and l-year cost data for 
the first 400 randomized patients are displayed below (see Table). Although DES 
reduced the rate of target vessel revascularization by 62% and follow-up costs by 
-$1500/pt, total l-year costs remained higher with DES ($14,245 vs. 513,642, pcO.001). 
The incremental C/E ratio for DES compared with BS was $5542 per repeat revascular- 
ization (RepRev) avoided-- similar to the C/E of BS for de nova lesions or brachytherapy 
for diffuse intrastent restenosis (-$5000 $10,000 per RepRev avoided). 
Conclusions 1) In a representative population of PCI patients, sirolimus DES Improved 
clinical outcomes but increased overall health care costs by -$600/pt compared with BS. 
2) Nonetheless, considering the quality of life benefits of avoiding restenosis. the C/E of 
DES compares reasonably with other accepted interventional techniques. 3) Comolete l- 
year data on the full 1100 pt trial will be available by 3103. 
Number of stentslpatient 
Cath lab cost 
Initial hosp. Cost 
l-year outcomes 
1.1*0.4 
$6225*1365 
510.704*2139 
Repeat revasc. (target vessel) 6.6% 
Repeat revasc (any vessel) 12.6% 
F/U cost 5354123204 
l-year total cost $14,246-3869 
Sirolimus Stent Bsrs Stent 
1.1*0.5 
$4179+1016 
$8611*1913 
17.6% 
23.3% 
$5040*5098 
513,84&5548 
P-value 
NS 
<O.OOl 
<O.OOl 
<O.OOl 
0.006 
<O.OOl 
<0.001 
* Adjusted to account for the availability of stent lengths up to 33mm in clinical practice 
9:45 a.m. 
so5_3 One-Year Follow-Up of the SIRIUS Study: A 
Randomized Study With the Sirolimus-Eluting BX 
VELOCITY in the Treatment of Patients With De- 
Novo Native Coronary Artery Lesions 
David R. Holmes. Jr., Martin B. Leon, Jeffrey W. Moses, Jay Midwall. Mel Clark, lgor 
Palacios, Mark Bates, John Lopez, Alan C. Yeung, Richard E. Kuntz, on behalf of the 
SIRIUS Trial Investigators, Mayo Cknic, Rochester, MN 
Background: The Sirolimus-eluting stent (SES) is emergmg as a potential solution to the 
problem of restenosis in a variety of patient populations. The SIRIUS trial is a 1056 
patient, multicenter, double blind study conducted in the US comparing the Sirolimus- 
eluting stent (SES) to the uncoated Bx VELOCITY (control). The interim results of the 
first 400 patients, previously presented, demonstrated the safety and effectiveness at 9 
months. Longer term follow-up of these patients is planned at 12 months, and annually 
out to five years to confirm the durability of this treatment of de nova native coronary 
artery lesions. Methods: From February to August, 2001, 1058 patients were enrolled at 
53 centers. The primary endpoint was target vessel failure (TVF) at 9 months. Other clin- 
ical, angiographic and IVUS endpoints were also evaluated. Baseline demographics on 
the entire cohort revealed a mean age of 62 years, 26.4% diabetics, 41.6% with multives- 
sel disease, 30.6% had a prior Ml. The average lesion length was 14.4mm and the refer- 
ence vessel diameter was 2.60mm. Results: Nine month clinical follow-up results are 
presented below (Table 1). Accordingly, sirolimus-eluting stents appear to be safe and 
effective at 9 months. Twelve-month clinical follow-up will be presented. 
